Education and Training
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
This phase 2-3 trial studies the utility of 68-gallium (68Ga)-prostate-specific membrane antigen 11 (PSMA-11) positron emission tomography/magnetic resonance imaging (PET/MRI) to find tumors in patients with prostate cancer who are undergoing resection surgery for prostate cancer that is prognostically expected to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures, such as PET/MRI, may help find and diagnose prostate cancer, and reveal out how far the disease has spread. Radioactive drugs, such as 68Ga-PSMA-11, may bind to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (CT) or MRI scan.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: 68Ga-PSMA-11
- procedure: Magnetic resonance imaging (MRI)
- procedure: Positron Emission Tomography (PET)
Eligibility
INCLUSION CRITERIA
- Biopsy-proven prostate adenocarcinoma
- Planned prostatectomy with lymph node dissection
- Intermediate- to high-risk disease (as determined by elevated prostate-specific
antigen (PSA) [PSA > 10], T stage [T2b or greater], Gleason score [Gleason score > 6]
or other risk factors)
- Karnofsky performance status of ≥ 50 [or Eastern Cooperative Oncology Group
(ECOG)/World Health Organization (WHO) equivalent]
- Diagnostic CT or MRI performed within 90 days of the research PET
- Able to provide written consent
ExCLUSION CRITERIA
- Patients not capable of getting PET study due to weight, claustrophobia, or inability
to lay still for the duration of the exam
- Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy, including focal
ablation techniques (HiFu)
- Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging and
surgery
- Metallic implants (contraindicated for MRI)
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Male
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pranav Hegde
650-721-4080
Not Recruiting